Logo do repositório
 
Publicação

Investigating the impact of prior COVID-19 on IgG antibody and interferon γ responses after BBIBP-CorV vaccination in a disease endemic population: a prospective observational study

2023Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorHasan, Zahra
dc.contributor.authorMasood, Kiran Iqbal
dc.contributor.authorQaiser, Shama
dc.contributor.authorKhan, Erum
dc.contributor.authorHussain, Areeba
dc.contributor.authorGhous, Zara
dc.contributor.authorKhan, Unab
dc.contributor.authorYameen, Maliha
dc.contributor.authorHassan, Imran
dc.contributor.authorNasir, Muhammad Imran
dc.contributor.authorQazi, Muhammad Farrukh
dc.contributor.authorMemon, Haris Ali
dc.contributor.authorAli, Shiza
dc.contributor.authorBaloch, Sadaf
dc.contributor.authorBhutta, Zulfiqar A.
dc.contributor.authorVeldhoen, Marc
dc.contributor.authorSimas, J. Pedro
dc.contributor.authorMahmood, Syed Faisal
dc.contributor.authorGhias, Kulsoom
dc.contributor.authorHussain, Rabia
dc.date.accessioned2023-09-27T16:18:43Z
dc.date.available2023-09-27T16:18:43Z
dc.date.issued2023
dc.description.abstractBackground and Aims: COVID-19 vaccinations have reduced morbidity and mortality from the disease. Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) have been associated with immune protection. Seroprevalence studies revealed high immunoglobulin G (IgG) antibody levels to SARS-CoV-2 in the Pakistani population before vaccinations. We investigated the effect of BBIBP-CorV vaccination on circulating IgG antibodies and interferon (IFN)-γ from T cells measured in a cohort of healthy individuals, with respect to age, gender, and history of COVID-19. Methods: The study was conducted between April and October 2021. BBIBP-CorV vaccinated participants were followed up to 24 weeks. Antibodies to SARS-CoV-2 Spike protein and its receptor-binding domain (RBD) were measured. IFNγ secreted by whole blood stimulation of Spike protein and extended genome antigens was determined. Results: Study participants with a history of prior COVID-19 displayed a higher magnitude of IgG antibodies to Spike and RBD. IgG seropositivity was greater in those with prior COVID-19, aged 50 years or younger and in females. At 24 weeks after vaccination, 37.4% of participants showed IFN-γ responses to SARS-CoV-2 antigens. T cell IFN-γ release was higher in those with prior COVID-19 and those aged 50 years or less. Highest IFN-γ release was observed to extended genome antigens in individuals both with and without prior COVID-19. Conclusion: We found that IgG seropositivity to both Spike and RBD was affected by prior COVID-19, age and gender. Importantly, seropositive responses persisted up to 24 weeks after vaccination. Persistence of vaccine induced IgG antibodies may be linked to the high seroprevalence observed earlier in unvaccinated individuals. Increased T cell reactivity to Spike and extended genome antigens reflects cellular activation induced by BBIBP-CorV. COVID-19 vaccination may have longer lasting immune responses in populations with a higher seroprevalence. These data inform on vaccination booster policies for high-risk groups.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.1002/hsr2.1521pt_PT
dc.identifier.eid85170044467
dc.identifier.issn2398-8835
dc.identifier.pmcPMC10486204
dc.identifier.pmid37692793
dc.identifier.urihttp://hdl.handle.net/10400.14/42685
dc.identifier.wos001065207000001
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCOVID-19
dc.subjectImmunoglobulin G
dc.subjectInterferons
dc.subjectT-lymphocytes
dc.subjectVaccination
dc.titleInvestigating the impact of prior COVID-19 on IgG antibody and interferon γ responses after BBIBP-CorV vaccination in a disease endemic population: a prospective observational studypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue9pt_PT
oaire.citation.titleHealth Science Reportspt_PT
oaire.citation.volume6pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
75214043.pdf
Tamanho:
1.48 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
3.44 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

CBR - Contribuições em Revistas Científicas / Contribution to Journals